COMPANY:

NanoString Technologies

"NanoString Technologies, Inc...announced that substantially all of its assets will be acquired by Bruker Corporation...for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities...The acquisition by Bruker validates NanoString’s market-leading technology and ensures continuity of NanoString’s business operations and product development initiatives for customers and substantially all of its employees."

"NanoString Technologies, Inc...will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024....NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms."

"NanoString Technologies, Inc...announced that it has reached an agreement with Patient Square Capital ('Patient Square')...pursuant to which Patient Square will serve as the 'stalking horse' bidder in conjunction with a court-supervised sales process."

"NanoString Technologies, Inc...announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry’s first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), NanoString and independent researchers will also highlight recently achieved whole transcriptome imaging capability - the pinnacle of spatial biology - at the Advances in Genome Biology and Technology (AGBT) General Meeting, February 5-8 in Orlando, Florida."

"NanoString Technologies, Inc...announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager (SMI)...This technological milestone was accomplished using the CosMx SMI platform allowing researchers to simultaneously visualize the expression of every protein-coding gene in the human genome in situ, providing the ultimate capability for single cell spatial biology."

"10x Genomics, Inc...announced...that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc...In awarding over $31 million in damages, the jury found that NanoString's GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection willfully infringe all seven asserted patents owned by Prognosys and exclusively licensed to 10x Genomics."

"A*STAR’s Genome Institute of Singapore (GIS), NanoString® Technologies, Inc...and Next Level Genomics (NLG)...announced the establishment of a joint laboratory in Singapore focusing on the application of spatial biology to identify biomarkers that can predict disease progression and treatment response. The new lab, called the SpACE-Dx lab (Spatial Atlas of Clinical Evolution of Disease), will harness spatial multiomic (gene and protein expression) technologies to drive research in complex diseases, with a primary focus on cancer."

"Owkin, Nanostring...and world-leading cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg, and Charité - Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting (booth #4037). MOSAIC is a landmark $50 million project to revolutionize cancer research through the use of spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors."

"NanoString Technologies, Inc...and Visiopharm...announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. Together, NanoString and Visiopharm are developing integrated workflows leveraging the multiplexing capability of the GeoMx® Digital Spatial Profiler (DSP) and the AI-driven image analysis capabilities of Visiopharm. NanoString’s new cloud informatics platform, the AtoMx™ Spatial Informatics Platform, will enhance the integration by providing scalable computing power with worldwide access."

"NanoString Technologies, Inc...announced a peer-reviewed paper published in Nature Genetics using the GeoMx Human Whole Transcriptome Atlas (WTA) to construct a high-resolution molecular landscape of pancreatic cancer. This paper, along with a tissue image generated using the GeoMx® Digital Spatial Profiler (DSP), is featured on the cover of the August 2022 edition of Nature Genetics."

"NanoString Technologies, Inc...announced the highlights of over 125 studies enabled by NanoString platforms that will be presented at the 2022 meeting of the American Association of Cancer Research (AACR), which will be held April 8-13, 2022...These abstracts include at least 36 studies exploring spatial biology using the CosMx™ Spatial Molecular Imager (SMI) and GeoMx® Digital Spatial Profiler (DSP), and 59 studies exploring gene expression using the nCounter® Analysis System."